- Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said the first patient was dosed in a phase 2 trial of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).
- The study will evaluate the efficacy and safety of two doses (8 mg/kg or 12 mg/kg) of DS-7300, an antibody drug conjugate, in patients with extensive-stage SCLC who have received at least one prior line of platinum-based chemotherapy.
- The main goal of the trial — which will enroll ~80 patients across Asia, Europe and North America — is to check the objective response rate.
For further details see:
Daiichi Sankyo begins dosing in mid-stage study of DS-7300 for lung cancer